Clinical trials: Delayed Gastric Emptying
Gastroparesis
Enterra Therapy Clinical Study (Gastric Stimulation for Gastroparesis)
This study is to evaluate the safety and effectiveness of gastric stimulation in the reduction of nausea and vomiting in patients with gastroparesis using an approved Humanitarian device.
- Trial name
- NCT00157755
- Testing
- Enterra Therapy
- Where
- 6 sites in United States
- Volunteers
- 87 people
- Sponsor
- MedtronicNeuro
Gastrointestinal Diseases, Stomach Diseases
A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time
The purpose of this study is to determine the correlation between gastric residence time of the SmartPill Capsule and the time required for partial emptying of a standard radiolabeled meal as measured by gastric emptying…
- Conditions
- Gastrointestinal Diseases, Stomach Diseases, Gastroparesis
- Trial name
- NCT00128284
- Where
- 7 sites in United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- The SmartPill Corporation
Gastroparesis
Diabetic Gastroparesis Study 05
This open-label study is to assess the safety of continued treatment with relamorelin for participants who previously completed the RLM-MD-03 [NCT03420781] or RLM-MD-04 [NCT03383146] study and to provide treatment for these…
- Trial name
- NCT03786380
- Testing
- Relamorelin 10 μg
- Where
- 486 sites in United States, Argentina and 28 more
- Volunteers
- 202 people
- Sponsor
- Allergan
Gastroparesis
An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options
The purpose of this study is to assess the effectiveness of cisapride in patients with a primary diagnosis of chronic gastroparesis (a stomach disorder) of unknown cause.
- Trial name
- NCT01281540
- Testing
- Cisapride
- Volunteers
- 20 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetic Gastroparesis
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis
This is a single blind phase 2a study to evaluate the safety, tolerability, pharmacokinetics, and exploratory efficacy of nimacimab in patients with diabetic gastroparesis.
- Trial name
- NCT03900325
- Testing
- Nimacimab
- Where
- 5 sites in United States
- Volunteers
- 6 people
- Sponsor
- Bird Rock Bio, Inc.
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.
- Conditions
- Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
- Trial name
- NCT01394055
- Testing
- RM-131
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Motus Therapeutics, Inc.
Gastroparesis, Diabetes
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis treated with tegaserod over 2 weeks.
- Trial name
- NCT00390975
- Testing
- Tegaserod
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis
Gastroparesis
FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers
This study is the First Time In Human study for the motilin receptor agonist, GSK1322888. GSK1322888 is a potent and selective small molecule motilin receptor agonist, distinct from the motilide compound structures.
- Trial name
- NCT01294566
- Testing
- GSK1322888
- Where
- Australia
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gastroparesis
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
This study is a randomized, double-blind, placebo controlled trial designed to confirm the symptomatic effects of camicinal treatment vs. placebo, on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis.
- Trial name
- NCT02210000
- Testing
- Camicinal
- Where
- 34 sites in United States
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Gastroparesis
Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers
The purpose of this study is to evaluate the safety and establish the pharmacokinetic (PK) profile of C13-URA in healthy volunteers
- Trial name
- NCT01074710
- Testing
- [2-13C] uracil
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Diabetic Gastroparesis
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered…
- Trial name
- DIGEST (NCT01664637)
- Testing
- 10 mg TZP-102
- Where
- 35 sites in United States, Poland
- Volunteers
- 120 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis
The purpose of this study is to determine whether TZP-101 is safe in people with diabetes. Also to determine if TZP-101 is effective in increasing the gastric emptying rate in diabetic patients.
- Trial name
- NCT00639808
- Testing
- 5% dextrose in water, TZP-101
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 10 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis, Gastroparesis Nondiabetic
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life…
- Conditions
- Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
- Trial name
- EXPEDITE (NCT06560307)
- Testing
- Enterra Therapy System
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterra Medical, Inc.
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis
The purpose of this study is to determine whether TZP-101 is effective in the treatment of symptomatic gastroparesis due to diabetes.
- Trial name
- NCT00612014
- Testing
- 5% dextrose in water, TZP-101
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 78 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.
This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses of GSK962040.
- Trial name
- NCT00733551
- Testing
- GSK962040
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetic Gastroparesis
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.
- Trial name
- NCT05832151
- Testing
- CIN-102 Dose 15mg or 10mg
- Where
- 100 sites in United States
- Volunteers
- 382 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis
Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study
This is a multi-center, parallel group, placebo-controlled and active-compared, randomized study to assess the ability of GSK962040 to enhance the delivery of enteral feed to critically ill subjects that are predisposed to…
- Trial name
- NCT01934192
- Testing
- GSK962040 50 mg, Metoclopramide 10 mg
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- GlaxoSmithKline
Diabetic Gastroparesis, Idiopathic Gastroparesis
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
- Trial name
- NCT03281577
- Testing
- TAK-954
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Takeda